Last update 17 May 2024

Socazolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
PD-L1 monoclonal antibody, 首克注利单抗, STI-1014
+ [5]
Target
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (CN)
Login to view First Approval Timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Cervical Carcinoma
CN
19 Dec 2023
Recurrent Cervical Cancer
CN
19 Dec 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Extensive stage Small Cell Lung CancerPhase 3
CN
15 Jul 2021
OsteosarcomaPhase 3-01 Jun 2020
Metastatic melanomaPhase 2
CN
27 Sep 2021
Esophageal Squamous Cell CarcinomaPhase 2
CN
18 Nov 2020
Metastatic urothelial carcinomaPhase 2
CN
10 Oct 2018
Transitional Cell CarcinomaPhase 2
CN
10 Oct 2018
Biliary Tract NeoplasmsPhase 1
CN
01 Feb 2021
Advanced Urothelial CarcinomaPhase 1
CN
14 Sep 2020
Metastatic Carcinoma to the Uterine CervixPhase 1
CN
16 Aug 2018
NeoplasmsPreclinical
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
20
hjgtbzvcgw(vzfjdpjtaw) = vvqtpiihix tqgmmydkmv (xqzqxivufv, 45.72% - 88.11)
-
01 Apr 2023
Phase 1
-
lgiplgvyph(qzjcnwcdrd) = kcnjynwbko uuobrzyzlp (bnxigbcfwc, 8.7 - 24.5)
Positive
22 Sep 2022
Phase 2
64
Socazolimab+nab-paclitaxel+cisplatin
dvxhhreaut(gpocucvuoj) = sjdnmpxkqc xgnyqkxabd (oabdhmpakd )
Positive
10 Sep 2022
placebo+nab-paclitaxel+cisplatin
dvxhhreaut(gpocucvuoj) = wuqxfjojut xgnyqkxabd (oabdhmpakd )
Not Applicable
-
Atezolizumab plus carboplatin and etoposide (ACE)
wvnrwvoczi(lpqntbapzu) = nkiehlsmqu mhznqrsqts (usxzvannls )
-
10 Sep 2022
Phase 1
20
svtwhtouuq(ibcjkeamvw) = lbjaabcdlp ratcunpmkx (aojyyhqxbe )
Positive
02 Jun 2022
Phase 1
104
( dose-expansion phase)
vmracdrcpq(uxypghmuya) = fqaxtkdgif iublafsqzw (ridzjnjbsu )
Positive
02 Jun 2022
(CPS < 1)
vmracdrcpq(uxypghmuya) = qamsvlwdta iublafsqzw (ridzjnjbsu )
Phase 1
20
ebxxiijapi(hcosuwlrgf) = ybxwrxvvwi fdjjhdvuto (wkyjonrjas )
Positive
03 Apr 2022
Phase 1
-
abeiszqqam(ymodqnawkf) = jbqxdzzsbm zosagqvcen (oisfwougob, 10.9 - 27.4)
Positive
01 Nov 2021
Phase 1
20
rqafincvch(qvgtauxytk) = 最常见治疗相关不良事件包括血小板计数降低(30.0%)、贫血(25%)、中性粒细胞计数降低(20%)、高血糖症(20%)和白细胞计数降低(20%) jpotqqrbgo (llhfhdlxlz )
-
25 Sep 2021
Phase 2
60
ytgxdqowvu(thvctxzqyq) = 31/60(51.7%)名患者出现一项或多项治疗相关不良反应(TRAEs),大部分TRAEs为1或2级,仅有2患者(3.3%)出现3级或以上TRAEs。最常见的TRAEs包括状腺功能减退症(8例,13.3%),白细胞计数降低(6例,10.0%),类风湿因子升高(5例,8.3%),贫血(4例,6.7%)和天门冬氨酸氨基转移酶升高(3例,5.0%)。1人因为不良事件而退组。 uesvfushhp (aehepatatf )
-
19 Sep 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free